hvsa
Home
Courses
Course Objectives
Programs
CME Credits
Cases and Abstract Submissions
venue and accomodations
HVSA
Directors and Faculty
Videos
Register

 

New York City Conference

Back to 2014 Annual Meeting Abstracts


18-Year Experience with the Carpentier-Edwards PERIMOUNT Standard Aortic Valve at a Single Japanese Center
Koichi Arinaga, Koji Akasu, Hiriyuki Saisho, Toru Takaseya, Kumiko Wada, Hidetoshi Akasi, Hiroyuki Tanaka.
Kurume University School of Medicine, Kurume, Japan.

18-Year Experience with the Carpentier-Edwards PERIMOUNT Standard Aortic Valve at a Single Japanese Center Background: The aim of this study was to evaluate the long-term results of the Carpentier-Edwards Pericardial (CEP) Standard valve at the aortic position. Methods: From January 1996 to December 2010, 275 patients who underwent aortic valve replacement with the CEP valve were enrolled. A 19-mm valve was used in 42 patients, 21-mm valve in 103 patients, 23-mm valve in 97 patients, and 25-mm valve in 33 patients. The early and late results were evaluated. Echocardiography was performed at follow-up in 191 of 270 late survivors for a mean duration of 6.3 ± 3.2 years. Left ventricular mass index (LVMI), mean pressure gradient (MPG), and effective orifice area index (EOAI) were measured. Results: There were 5 early deaths (early mortality rate , 1.82%). Among the 270 survivors, 255 (94.4%) were followed-up for a mean duration of 7.4 years (range, 18 months to 17.2 years) for a total of 2037 patient-years. There were 80(29.6%) late deaths during the follow-up period. Cardiac death and valve-related death occurred in 35 patients. Actuarial survival at 10, and 15 years was 63.6% and 45.3%, respectively. Thromboembolism was observed in 17 patients (0.83%/patient-year), prosthetic endocarditis in 3 patients (0.15%/ p-y), structural valve deterioration in 6 patients (0.29%/ p-y), and reoperation in 9 patients (0.44%/p-y). Actuarial freedom from thromboembolism, prosthetic endocarditis, structural valve deterioration and reoperation at 15 years was 83.7, 98.7, 85.1 and 77.9%, respectively. Echocardiography revealed acceptable pressure gradients across the valve prosthesis in each valve size. MPG was 12.0 ± 3.5 mmHg (19mm), 9.9 ± 3.4 mmHg (21mm), 11.4 ± 6.4 mmHg (23mm), and 9.7 ± 2.5 mmHg (25mm). EOAI was 0.83 ± 0.13 cm2 (19mm), 1.00 ± 0.20 cm2 (21mm), 1.05 ± 0.22cm2 (23mm), and 1.11 ± 0.21 cm2 (25mm). LVMI decreased significantly in all valve sizes. Conclusion: The long-term results of CEP bioprosthesis in the aortic position were satisfactory. The hemodynamic performance of the CEP bioprosthesis is maintained even as late as 18 years after implantation.


Back to 2014 Annual Meeting Abstracts

     

Home | Courses | Objectives | Program | CME Credit | Cases & Abstracts | Venu & Accomodations | HVSA | Committee & Faculty | Register | Privacy Policy